OptiBiotix Health (OPTI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 17.75p
   
  • Change Today:
      0.000p
  • 52 Week High: 39.00
  • 52 Week Low: 6.00
  • Currency: UK Pounds
  • Shares Issued: 97.94m
  • Volume: 0
  • Market Cap: £17.38m

OptiBiotix Health extends terms of licence agreement with OptiPharm

By Josh White

Date: Wednesday 05 Aug 2020

LONDON (ShareCast) - (Sharecast News) - Life sciences company OptiBiotix Health has extended the terms of its original exclusive licence agreement for 'OptiBiome' with OptiPharm, it said on Wednesday, which was initially announced on 31 March.
The AIM-traded firm said the terms of the exclusive licence agreement signed in March granted OptiPharm exclusive use of the OptiBiome trademark in Australia, parts of Asia, New Zealand, the Middle East, the Gulf states and North America.

It said the extension of terms now included Europe, with market exclusivity still linked to minimum order quantities.

OptiBiotix described OptiPharm as a privately owned Australian company, which has been operating for 24 years and specialises in weight management, nutrition and infant formula.

It said its products were produced in "state-of-the-art" Australian manufacturing facilities that are 'Good Manufacturing Practice' (GMP) qualified and 'Hazard Analysis and Critical Control Point' (HACCP) certified.

OptiPharm's flagship brand , Optislim, is the number one weight management brand in the Australian market, incorporating shakes, soups and bars available as total or partial meal replacements.

Optislim is used by consumers in Australia, New Zealand, China, shortly the Middle East and the United Arab Emirates, and was set for release throughout south east Asia, North America and Europe.

"We will shortly be releasing a new range of Optislim products which will include OptiBiotix's patented ingredient for weight management, and are delighted that OptiBiotix has agreed to an extension of terms that provides unrestricted access to additional international markets," said OptiPharm managing director Garry McDonald.

Dr Fred Narbel, managing director of OptiBiotix's prebiotics division, added that the company was "very pleased" with the extension of terms for OptiPharm, adding that it strengthened the commercial relationship between both companies.

"It is also another important commercial step in bringing OptiBiotix's patented and award-winning, scientifically formulated functional ingredients to global markets with Australia's number one weight management brand."

At 1307 BST, shares in OptiBiotix Health were down 3.27% at 53.2p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OPTI Market Data

Currency UK Pounds
Share Price 17.75p
Change Today 0.000p
% Change 0.00 %
52 Week High 39.00
52 Week Low 6.00
Volume 0
Shares Issued 97.94m
Market Cap £17.38m

OPTI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
59.00% above the market average59.00% above the market average59.00% above the market average59.00% above the market average59.00% above the market average
92.45% above the sector average92.45% above the sector average92.45% above the sector average92.45% above the sector average92.45% above the sector average
Price Trend
21.86% below the market average21.86% below the market average21.86% below the market average21.86% below the market average21.86% below the market average
36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average
Income Not Available
Growth
96.31% below the market average96.31% below the market average96.31% below the market average96.31% below the market average96.31% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

OPTI Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

OPTI Key Personnel

CEO Stephen O'Hara
Finance Director Graham Myers

Top of Page